Gerald Ho, MD
Rheumatology · la Palma, CANPI 1205833662
Payments from drug & device makers
Across 835 payments — averaging $4290.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$991K
- UCB SA$587K
- AbbVie$555K
- E.r. Squibb & Sons, L.L.C.$510K
- Janssen Research & Development, LLC$491K
- Pfizer$274K
- plus $175K from 28 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 68 | $990,670 |
| UCB SA | 61 | $586,927 |
| AbbVie | 166 | $554,516 |
| E.r. Squibb & Sons, L.L.C. | 24 | $510,477 |
| Janssen Research & Development, LLC | 112 | $490,930 |
| Pfizer | 110 | $273,982 |
| AstraZeneca(2 entities) | 11 | $120,125 |
| GSK | 7 | $26,284 |
| EMD Serono, Inc. | 2 | $12,230 |
| Radius Health, Inc. | 30 | $9,868 |
| Amgen(2 entities) | 151 | $2,238 |
| Ablynx NV | 1 | $2,000 |
| Biogen | 1 | $864 |
| Johnson & Johnson(2 entities) | 21 | $283 |
| Bristol Myers Squibb | 19 | $239 |
| Mallinckrodt Enterprises LLC | 10 | $172 |
| Lilly USA, LLC | 5 | $98 |
| ANI Pharmaceuticals, Inc. | 2 | $77 |
| Merck | 5 | $75 |
| UCB, Inc. | 3 | $68 |
| Genentech USA, Inc. | 4 | $68 |
| Zimmer Biomet | 2 | $48 |
| Medexus Pharma, Inc. | 3 | $46 |
| Fidia Pharma USA Inc. | 3 | $44 |
| Gilead | 2 | $43 |
| Sanofi | 2 | $40 |
| Ferring Pharmaceuticals Inc. | 2 | $35 |
| Boston Scientific | 2 | $30 |
| Abbott | 1 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Sobi, Inc | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $13 |
| Forte Bio-pharma LLC | 1 | $13 |
| Organon | 1 | $7 |
How this compares
$3,582,571 in reported general payments places this provider in the 95th percentile of 808 rheumatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in la Palma
- Samy MetyasCovina$12.9M
- Christine ThaiHuntington Beach$8.5M
- Tien-I SuWhittier$8.4M
- Eric LeeUpland$6.9M
- Orrin TroumSanta Monica$6.9M
- Shirley PangFullerton$5.7M
- William RobinsonStanford$5.1M
- Dan laTujunga$5.1M
- Christina Charles-SchoemanLos Angeles$4.8M
- Suneet GrewalWest Hollywood$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.